eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | neutropenia |
| Comorbidity | C1140680|ovarian cancer |
| Sentences | 2 |
| PubMedID- 24657302 | Objective: evaluate the cost-effectiveness of primary prophylaxis (pp) or secondary prophylaxis (sp) with pegfilgrastim, filgrastim (6-day and 11-day), or no prophylaxis to reduce the risk of febrile neutropenia (fn) in patients with recurrent ovarian cancer receiving docetaxel or topotecan. |
| PubMedID- 24761216 | Clinical trials have reported that the incidence of febrile neutropenia in patients with ovarian cancer receiving paclitaxel and carboplatin (tc) chemotherapy is<10% [9,10], and the guidelines indicate that csfs are not needed for primary prophylaxis in these patients. |
Page: 1